Analysts Set ICU Medical, Inc. (NASDAQ:ICUI) Target Price at $170.25

ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) has received a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $170.25.

ICUI has been the subject of a number of research reports. KeyCorp lifted their target price on shares of ICU Medical from $147.00 to $198.00 and gave the company an "overweight" rating in a research note on Tuesday, October 15th. Raymond James boosted their target price on ICU Medical from $158.00 to $190.00 and gave the company an "outperform" rating in a research note on Thursday, September 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of ICU Medical in a research note on Thursday, October 10th. StockNews.com upgraded ICU Medical from a "hold" rating to a "buy" rating in a report on Thursday, September 12th. Finally, Jefferies Financial Group initiated coverage on shares of ICU Medical in a report on Monday, October 14th. They issued a "hold" rating and a $183.00 price objective for the company.

Insider Transactions at ICU Medical

In related news, VP Virginia Ruth Sanzone sold 2,050 shares of the company's stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total value of $295,425.50. Following the completion of the transaction, the vice president now directly owns 4,482 shares in the company, valued at approximately $645,901.02. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,050 shares of the company's stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total value of $295,425.50. Following the sale, the vice president now directly owns 4,482 shares in the company, valued at $645,901.02. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of the company's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total value of $2,141,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares in the company, valued at $18,665,666.78. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 40,552 shares of company stock worth $6,679,322 over the last three months. 6.70% of the stock is currently owned by insiders.

Institutional Trading of ICU Medical

Large investors have recently made changes to their positions in the business. Motco bought a new stake in shares of ICU Medical during the first quarter worth $29,000. Innealta Capital LLC bought a new stake in shares of ICU Medical during the second quarter worth $32,000. GAMMA Investing LLC grew its holdings in shares of ICU Medical by 75.1% during the first quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier's stock worth $33,000 after purchasing an additional 133 shares during the last quarter. Hexagon Capital Partners LLC grew its holdings in shares of ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier's stock worth $36,000 after purchasing an additional 122 shares during the last quarter. Finally, Allworth Financial LP grew its holdings in shares of ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier's stock worth $36,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 96.10% of the company's stock.

ICU Medical Trading Down 1.2 %

Shares of ICU Medical stock traded down $2.22 on Thursday, reaching $175.48. 162,912 shares of the company were exchanged, compared to its average volume of 277,533. The stock has a fifty day moving average price of $171.90 and a 200-day moving average price of $133.88. The firm has a market capitalization of $4.28 billion, a price-to-earnings ratio of -72.53 and a beta of 0.66. The company has a current ratio of 2.41, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76. ICU Medical has a fifty-two week low of $78.28 and a fifty-two week high of $188.53.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.56. The company had revenue of $596.50 million for the quarter, compared to analyst estimates of $556.64 million. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. ICU Medical's revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.58 earnings per share. On average, analysts expect that ICU Medical will post 3.76 EPS for the current year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.